课题基金 / 基金详情

EFFICACY OF TA-3090 IN THE TREATMENT OF PATIENTS WITH INTERMITTENT CLAUDICATION

EFFICACY OF TA-3090 IN THE TREATMENT OF PATIENTS WITH INTERMITTENT CLAUDICATION
TA-3090 治疗间歇性跛行患者的疗效
批准号：
3864920
负责人：
JOHN M. PORTER
金额：
$0.0万
依托单位：
OREGON HEALTH & SCIENCE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/3864920
关键词：
artery occlusion calcium channel blockers cardiovascular disorder chemotherapy drug screening /evaluation human subject human therapy evaluation limb movement limbs pain vasodilators

项目摘要

项目成果

JOHN M. PORTER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Intermittent claudication is one of the early signs of chronic occlusive arterial disease. TA-3090 is a peripheral vasodilator which is also known to increase RBC deformability. This combination of actions is felt to be of benefit in claudicators, and may lead to an increase in walking capacity without the necessity of surgery or angioplasty.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CHRONIC ADMINISTRATION OF CILOSTAZOL IN PATIENTS WITH INTERMITTENT CLAUDICATION
DIAGNOSIS, PATHOPHYSIOLOGY AND CLINICAL COURSE OF RAYNAUD'S SYNDROME
NATURAL HISTORY OF RAYNAUD'S SYNDROME
NATURAL HISTORY OF RAYNAUD'S SYNDROME
海外基金